Jemperli received breakthrough therapy designation by the FDA for locally advanced mismatch repair deficient/microsatellite ...
Patients newly diagnosed with multiple myeloma who are transplant ineligible or deferred may benefit from receiving a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback